New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 21, 2017 – The FDA announced the approval of La Jolla Pharmaceutical's Giapreza (angiotensin) to increase blood pressure (BP) in adults with septic shock or other distributive shock.
Download PDF
Return to publications
